NRX Pharmaceuticals (Nasdaq:Nrxp) to Proceed With Two New Drug Applications in 2024; NRX-101 Has Been Returned to the Company for Filing
NRX藥品(納斯達克:Nrxp)將在2024年繼續提交兩份新的藥物申請; NRX-101已歸還公司進行歸檔。
NRX Pharmaceuticals (Nasdaq:Nrxp) to Proceed With Two New Drug Applications in 2024; NRX-101 Has Been Returned to the Company for Filing
NRX藥品(納斯達克:Nrxp)將在2024年繼續提交兩份新的藥物申請; NRX-101已歸還公司進行歸檔。
譯文內容由第三人軟體翻譯。